Taylor Wessing advises the Debiopharm Group on an exclusive agreement with Cambridge Antibody Technology
23-Jan-2007 | Corporate, Life Sciences & Healthcare
CLIENT
Debiopharm Group
VALUE
Transaction ongoing
TRANSACTION
Licensing deal
DESCRIPTION
Advised Debiopharm Group on an exclusive agreement with Cambridge Antibody Technology to develop and market SC-1 for gastric carcinomas